A 75-year-old man with poorly differentiated adenocarcinoma in the right lower lobe received neoadjuvant carboplatin, paclitaxel, and nivolumab therapy. Although posttreatment CT scans suggested ...
Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sac-TMT reduced the risk of disease ...
Differentiated thyroid carcinoma (DTC) is typically indolent, and some patients may be managed conservatively without immediate surgery. However, it remains a clinical challenge to determine who is ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results